Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
11.98
-0.07 (-0.58%)
At close: Oct 23, 2026, 4:00 PM EDT
11.80
-0.18 (-1.50%)
After-hours: Oct 23, 2026, 7:30 PM EDT
Korro Bio Employees
Korro Bio had 57 employees as of June 30, 2026. The number of employees decreased by 35 or 38.04% compared to the same quarter last year. That makes Korro Bio the 34,487th largest employer in the world and 4,580th in the United States.
Employees
57
Change (1Y)
-35
Growth (1Y)
-38.04%
Revenue / Employee
$41,789
Profits / Employee
-$1,870,947
Market Cap
176.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 57 | -35 | -38.04% | 57 | 0 |
| Mar 31, 2026 | 49 | -63 | -56.25% | 49 | 0 |
| Dec 31, 2025 | 58 | -46 | -44.23% | 58 | 0 |
| Sep 30, 2025 | 87 | -8 | -8.42% | 87 | 0 |
| Jun 30, 2025 | 92 | 0 | - | 92 | 0 |
| Mar 31, 2025 | 112 | 18 | 19.15% | 112 | 0 |
| Dec 31, 2024 | 104 | 2 | 1.96% | 104 | 0 |
| Sep 30, 2024 | 95 | -1 | -1.04% | 95 | 0 |
| Jun 30, 2024 | 92 | 4 | 4.55% | 92 | 0 |
| Mar 31, 2024 | 94 | 6 | 6.82% | 94 | 0 |
| Dec 31, 2023 | 102 | - | - | 101 | 1 |
| Sep 30, 2023 | 96 | - | - | 95 | 1 |
| Jun 30, 2023 | 88 | - | - | 88 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Entrada Therapeutics | 152 |
| Sutro Biopharma | 128 |
| Invivyd | 122 |
| Compugen | 75 |
| Alpha Cognition | 71 |
| Sionna Therapeutics | 59 |
| PepGen | 57 |
| Eledon Pharmaceuticals | 33 |
KRRO News
- 3 days ago - Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 3 days ago - Korro Bio management to meet virtually with Oppenheimer - TheFly
- 8 days ago - Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Korro Bio management to meet with Piper Sandler - TheFly
- 19 days ago - Korro Bio doses first cohort of participants in KRRO-121 trial - TheFly
- 19 days ago - Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 - GlobeNewsWire
- 6 weeks ago - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 month ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire